BRILINTA IS INDICATED TO HELP PROTECT MI PATIENTS FROM ACUTE* AND LONG-TERM† THROMBOTIC CV EVENTS1
PLATO*: Patients with ACS treated up to 12 months1,2
BRILINTA 90 mg‡ plus aspirin significantly reduced the primary composite end point of CV death, MI, or stroke by 16% RRR (ARR 1.9%) vs clopidogrel plus aspirin at 12 months (9.8% vs 11.7% [HR: 0.84, 95% CI: 0.77–0.92]; P=0.0003). The difference in treatments was driven by CV death and MI with no difference in stroke.
Bleeding§ in the PLATO trial1,2
PLATO-defined Non–CABG-related Major plus Minor Bleeding for BRILINTA 90 mg plus aspirin vs clopidogrel plus aspirin was (7.7% vs 6.2%) and for Non–CABG-related Major Bleeding (3.9% vs 3.3%), respectively. About half of the Non–CABG-related Major bleeding events were in the first 30 days.
The PLATO trial did not show an advantage for BRILINTA 90 mg compared with clopidogrel for CABG-related Bleeding (Total Major 81.3% vs 81.8% and
Fatal/Life-threatening 43.8% vs 43.0%, respectively).
When antiplatelet therapy was stopped 5 days before CABG, Major Bleeding occurred in 75% of patients treated with BRILINTA 90 mg and 79% of patients on clopidogrel.
PEGASUS†: Patients with prior MI treated up to
BRILINTA 60 mg¶ plus aspirin significantly reduced the primary composite end point of CV death, MI, or stroke by 16% RRR (ARR 1.27%) vs placebo plus aspirin at 3 years (7.8% vs 9.0% [HR: 0.84, 95% CI: 0.74–0.95]; P=0.0043).
BleedingII in the PEGASUS trial1,3
In PEGASUS, TIMI Major Bleeding rates were 1.7% for BRILINTA 60 mg plus aspirin vs 0.8% for placebo plus aspirin. TIMI Major or Minor Bleeding rates were 2.4% for BRILINTA 60 mg plus aspirin vs 1.0% for placebo plus aspirin.
ACS treated up to
Patients with prior
MI treated up to